Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
27 févr. 2024 07h58 HE
|
Clearmind Medicine Inc.
New patent applications build upon Clearmind’s broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE:...
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
14 juil. 2023 07h55 HE
|
SciSparc Ltd
“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel" TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
07 juin 2023 08h05 HE
|
SciSparc Ltd
TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
07 juin 2023 08h05 HE
|
Jeffs' Brands Ltd
Tel Aviv, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company” or “Jeffs' Brands”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today...
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
22 févr. 2023 08h00 HE
|
SciSparc Ltd
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
22 févr. 2023 08h00 HE
|
Clearmind Medicine Inc.
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...